FIELD: medicine.
SUBSTANCE: invention refers to molecular biotechnology and medicine. There are described methods of treating an autoimmune disease. The methods provide administering a pharmaceutical composition containing CD4 humanised antibody. The antibody is able to activate CD4+ CB25+ regulatory T-cells.
EFFECT: presented group of inventions can be used in medicine.
33 cl, 41 dwg, 20 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR TREATING DISEASE | 2009 |
|
RU2540013C2 |
| AGENT FOR DISEASE TREATMENT | 2009 |
|
RU2540018C2 |
| COMPOSITION FOR TREATING DISEASE | 2009 |
|
RU2531548C2 |
| DRUGS FOR TREATING DISEASES | 2010 |
|
RU2598719C2 |
| HUMANISED AHTH-CD4 ANTIBODY WITH IMMUNOSUPPRESSIVE PROPERTIES | 2004 |
|
RU2375375C2 |
| LIGAND GITR AND MOLECULES AND ANTIBODIES BOUND WITH LIGAND GITR, AND VERSIONS OF THEIR APPLICATION | 2004 |
|
RU2369636C2 |
| HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2587622C2 |
| MUCOSAL INDUCTION OF ANTIGEN TOLERANCE | 2006 |
|
RU2420569C2 |
| METHOD OF TREATING PSORIASIS (VERSIONS) | 2009 |
|
RU2497545C2 |
| INDUCTION OF IMMUNE TOLERANCE USING METHOTREXATE | 2012 |
|
RU2674036C2 |
